Nothing Special   »   [go: up one dir, main page]

BR9713925A - Composto, processo para preparação de um composto, e, composição farmacêutica - Google Patents

Composto, processo para preparação de um composto, e, composição farmacêutica

Info

Publication number
BR9713925A
BR9713925A BR9713925A BR9713925A BR9713925A BR 9713925 A BR9713925 A BR 9713925A BR 9713925 A BR9713925 A BR 9713925A BR 9713925 A BR9713925 A BR 9713925A BR 9713925 A BR9713925 A BR 9713925A
Authority
BR
Brazil
Prior art keywords
compound
pct
preparing
pharmaceutical composition
date jun
Prior art date
Application number
BR9713925A
Other languages
English (en)
Inventor
Lo C Foulon
Claudine Serradeil-Le Gal
Gerard Valette
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR9713925A publication Critical patent/BR9713925A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

O, E, COMPOSIçãO FARMACêUTICA". A invenção tem porara sua preparação e as composições farmacêuticas contendo os mesmos. Estes compostos apresentam uma vasopressina e/ou da ocitocina.
BR9713925A 1996-12-13 1997-12-11 Composto, processo para preparação de um composto, e, composição farmacêutica BR9713925A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9615384A FR2757157B1 (fr) 1996-12-13 1996-12-13 Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
PCT/FR1997/002270 WO1998025901A1 (fr) 1996-12-13 1997-12-11 Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
BR9713925A true BR9713925A (pt) 2000-03-21

Family

ID=9498678

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713925A BR9713925A (pt) 1996-12-13 1997-12-11 Composto, processo para preparação de um composto, e, composição farmacêutica

Country Status (11)

Country Link
US (1) US6090818A (pt)
EP (1) EP0950047B1 (pt)
JP (1) JP3330958B2 (pt)
AT (1) ATE252080T1 (pt)
AU (1) AU5488498A (pt)
BR (1) BR9713925A (pt)
CA (1) CA2274898A1 (pt)
DE (1) DE69725608T2 (pt)
FR (1) FR2757157B1 (pt)
NO (1) NO313551B1 (pt)
WO (1) WO1998025901A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9902376A3 (en) * 1999-07-15 2002-11-28 Sanofi Aventis Process for producing n-(1,1-dimethyl)-4-[[s'-ethoxi-4-cis-[2-(4-morpholino)-ethoxi]-2'-oxospiro[cyclohexane-1,3'-[3h]indole]-1'(2'h)yl]-sulfonyl]-3-methoxybenzamide and its salts
HU225150B1 (en) * 1999-07-15 2006-07-28 Sanofi Aventis Novel process for producing 2-methoxy-4-(t-butylaminocarbonyl)-benzenesulfonyl chloride
HUP9902374A3 (en) * 1999-07-15 2002-11-28 Sanofi Aventis Process for producing spiro[(4-cyclohexanone)-[3h]indol-2'[1'h]-on derivatives and intermediates
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
ES2288899T3 (es) * 2000-10-04 2008-02-01 Astellas Pharma Inc. Uso de un antagonista de vasopresina tal como conivaptan en la fabricacion de un medicamento para el tratamiento de la hipertension pulmonar.
IL159219A0 (en) 2001-06-18 2004-06-01 Applied Research Systems Pyrrolidine oxadiazole derivatives, their preparation and pharmaceutical compositions containing them
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
FR2874921B1 (fr) * 2004-09-09 2006-10-20 Sanofi Aventis Sa Derives de 3-spiro-indolin-2-one, leur preparation et leur application en therapeutique
CA2589363A1 (en) * 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
WO2006101937A1 (en) * 2005-03-18 2006-09-28 Janssen Pharmaceutica N.V. Acylhydrazones as kinase modulators
DE102005014904A1 (de) * 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
WO2006100082A2 (de) 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
WO2007063123A1 (de) 2005-12-02 2007-06-07 Abbott Gmbh & Co. Kg Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE102006040915A1 (de) * 2006-08-26 2008-03-20 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
JP5437070B2 (ja) * 2006-08-26 2014-03-12 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換ベンゾイミダゾロン誘導体、それを含む薬剤およびそれの使用
TWI315304B (en) * 2006-08-31 2009-10-01 Univ Taipei Medical Indoline-sulfonamides compounds
WO2008046046A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
TW200833695A (en) 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Use of spiro-oxindole compounds as therapeutic agents
EP2076514A1 (en) * 2006-10-12 2009-07-08 Xenon Pharmaceuticals Inc. Spiro (furo ý3, 2-c¨pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
JP5645217B2 (ja) * 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ５，６−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
US9023854B2 (en) 2007-12-07 2015-05-05 AbbVie Deutschland GmbH & Co. KG 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases
WO2009071687A1 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Amidomethyl-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
NZ587015A (en) 2007-12-27 2012-06-29 Abbott Gmbh & Co Kg Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
HUE025938T2 (en) 2008-10-17 2016-05-30 Xenon Pharmaceuticals Inc Spiro oxindole compounds and their use as therapeutic agents
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
MX2012004373A (es) 2009-10-14 2012-06-28 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol.
NZ601667A (en) 2010-02-26 2014-10-31 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
CN108137561B (zh) 2015-11-06 2021-03-26 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
WO2017076931A1 (en) * 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
WO2017076932A1 (en) * 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives useful in the treatment of cns diseases
LT3371168T (lt) 2015-11-06 2020-10-12 F. Hoffmann-La Roche Ag Indolin-2-ono dariniai

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226860A (en) * 1979-08-06 1980-10-07 American Home Products Corporation Spiroindolones
SE8200320L (sv) * 1981-01-29 1982-07-30 Delalande Sa Nya derivat av spiro-1 isobensofuraner och spiro-1 isobensotiofener, derasframstellningssett och terapeutiska anvendning
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2740136B1 (fr) * 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders

Also Published As

Publication number Publication date
EP0950047A1 (fr) 1999-10-20
AU5488498A (en) 1998-07-03
ATE252080T1 (de) 2003-11-15
CA2274898A1 (en) 1998-06-18
FR2757157B1 (fr) 1999-12-31
WO1998025901A1 (fr) 1998-06-18
EP0950047B1 (fr) 2003-10-15
NO313551B1 (no) 2002-10-21
US6090818A (en) 2000-07-18
DE69725608D1 (de) 2003-11-20
JP2000509723A (ja) 2000-08-02
JP3330958B2 (ja) 2002-10-07
NO992878L (no) 1999-08-10
DE69725608T2 (de) 2004-07-29
FR2757157A1 (fr) 1998-06-19
NO992878D0 (no) 1999-06-11

Similar Documents

Publication Publication Date Title
BR9713925A (pt) Composto, processo para preparação de um composto, e, composição farmacêutica
BR9303993A (pt) Composto, processo para preparar o mesmo e composição farmacêutica
BR0210464A (pt) Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto
BR9915132A (pt) Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica.
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
YU56995A (sh) Soli derivata indola
DE60112330D1 (en) Pyrazolopyridinderivate
NO954320L (no) Lyosfærer omfattende gonadotropin
YU41199A (sh) Hinoksalindioni
BR9508294A (pt) Composto de triazol processo para a preparação dos mesmos composição farmacêutica e utilização de pelo menos um composto
MX9604483A (es) Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
BR9807988A (pt) Processo para a preparação de um composto, e, composto.
BR9705456A (pt) Compostos heterocìclicos, processo de aminometila para sua preparação e composições farmacêuticas que os contêm.
DE60201074D1 (en) Pyrazolopyridinderivate
SE9904128D0 (sv) Novel compounds
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
BR9007981A (pt) Massa de revestimento,processo para sua preparacao assim como sua aplicacao
NO994135D0 (no) Kinoksalindioner
MX9302429A (es) Nuevas tetralonas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
TW371661B (en) Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
DE69416003D1 (en) Kristalline, polymorphische form von (s,s,s)-n-(1-[2-carboxy-3-(n2-mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosin
IL138638A0 (en) Processes for preparing intermediates
AR008474A1 (es) Derivado de 9-dihidroeritromicina a 6,9; 11,12-diciclocarbonato, composicion farmaceutica y preparacion bactericida que lo contienen y su uso
ES2140683T3 (es) Procedimiento para preparar compuestos de benzopirano.
UY26971A1 (es) Nuevos antagonistas de neuroquinina, procedimiento para su preparación y composiciones farmacéuticas que contienen estos compuestos

Legal Events

Date Code Title Description
PC Transfer

Free format text: SANOFI-SYNTHELABO (FR)

B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements